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Background 
Proximal hamstring tendinopathy affects athletic and non-athletic populations and is 
associated with longstanding buttock pain. The condition is common in track and field, 
long distance running and field-based sports. Management options need to be evaluated 
to direct appropriate clinical management. 
Purpose/Hypothesis 





Electronic databases were searched to January 2019. Studies (all designs) investigating 
interventions for people with proximal hamstring tendinopathy were eligible. Outcomes 
included symptoms, physical function, quality of life and adverse events. Studies were 
screened for risk of bias. Reporting quality was assessed using the Cochrane Risk of Bias 
Tool (Randomized Controlled Trials [RCT]) and the Joanna Briggs Institute Checklist (Case 
Series). Effect sizes (Standard mean difference or Standard paired difference) of 0.2, 0.5 
and 0.8 were considered as small, medium and large respectively. Overall quality of 
evidence was rated according to GRADE guidelines. 
Results 
Twelve studies (2 RCTs and 10 case series) were included (n=424; males 229). RCTs 
examined the following interventions: platelet-rich plasma injection (n=1), autologous 
whole-blood injection (n=1), shockwave therapy (n=1) and multi-modal intervention 
(n=1). Case series included evaluation of the following interventions: platelet-rich plasma 
injection (n=3), surgery (n=4), corticosteroid injection (n=2), multi-modal intervention + 
platelet-rich plasma injection (n=1). Very low-level evidence found shockwave therapy 
was more effective than a multi-modal intervention, by a large effect on improving 
symptoms (-3.22 SMD; 95% CI -4.28, -2.16) and physical function (-2.42 SMD; 95% 
CI-3.33, -1.50) in the long-term. There was very low-level evidence of no difference
between autologous whole-blood injection and platelet-rich plasma injection on physical
function (0.17 SMD; 95% CI -0.86, 1.21) to (0.24 SMD; 95% CI -0.76, 1.24) and quality of
life (-0.04 SMD; 95%CI -1.05, 0.97) in the medium-term. There was very low-quality
evidence that surgery resulted in a large reduction in symptoms (-1.89 SPD; 95% CI -2.36,
-1.41) to (-6.02 SPD; 95% CI -8.10, -3.94) and physical function (-4.08 SPD; 95%CI -5.53,
-2.63) in the long-term.
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Conclusions 
There is insufficient evidence to recommend any one intervention over another. A 
pragmatic approach would be to initially trial approaches proven successful in other 
tendinopathies. 
Level of evidence 
Level 2a 
INTRODUCTION
Proximal hamstring tendinopathy presents as persistent 
buttock pain that occurs with activities such as running, sit-
ting and lunging.1,2 The condition primarily affects active 
men and women3 in sports such as track and field, distance 
running, soccer and rugby.1 It also afflicts people who do 
not participate in sport.4,5 The condition is challenging to 
manage because of the persistence of symptoms and lack of 
response to treatment.3,6 
Interventions for proximal hamstring tendinopathy fo-
cus on reducing symptoms and restoring physical function. 
Common non-surgical interventions include exercise, cor-
ticosteroid injection, platelet-rich-plasma injection and 
shockwave therapy.6,7 Common surgical procedures include 
tenotomy, bursal and tendon debridement and removal of 
adhesions around the sciatic nerve.2,8 
With many treatment options available, a rational start-
ing point is to systematically review the literature and syn-
thesize information where possible. The purpose of this 
systematic review was to evaluate both surgical and non-
surgical interventions used in managing proximal ham-
string tendinopathy. 
METHODS
The systematic review protocol (Figure 1) was developed in 
accordance with the PRISMA statement and preregistered 
on PROSPERO (ID: CRD42017072678).9 
A systematic literature search was conducted from the 
earliest date available until January 2019 for relevant stud-
ies published in MEDLINE, CINAHL, EMBASE, SPORTSDIS-
CUS and PUBMED. A comprehensive search was undertak-
en, with assistance of a librarian, using a combination of 
keywords and medical subject headings (MeSH). The search 
strategy was formed around two topics; “hamstring” and 
“tendinopathy”. Synonyms within each concept were com-
bined with OR Boolean operator; and terms between con-
cepts were combined with AND Boolean operator (Appendix 
1). 
After removal of duplicates, two reviewers (AN and JA) 
independently scanned titles and abstracts of all papers. 
Any disagreement was referred to a third reviewer (AS) for 
consensus. Full text versions of articles were obtained for all 
remaining studies. To ensure all relevant articles were in-
cluded, citation tracking (PubMed/ Google Scholar) and ref-
erence checking of included studies was performed. 
Study designs included were randomized controlled tri-
als (RCTs), prospective (comparative) cohort studies, case-
control studies and case series with 10 or more participants. 
Articles were confined to English language only. Biome-
chanical reports and narrative reviews were excluded. Par-
ticipants of any age diagnosed with proximal hamstring 
tendinopathy by a health professional were included. Syn-
onyms considered included: hamstring tendinitis, high-
hamstring tendinopathy, and hamstring origin tendinopa-
thy. Traumatic injuries such acute proximal hamstring ten-
don tears, complete hamstring tears or avulsion injuries 
were excluded. 
Surgical and non-surgical interventions were considered 
in this review. Interventions included, but were not limited 
to: surgery, shockwave therapy, platelet-rich plasma injec-
tions, autologous whole blood injections, corticosteroid in-
jection and multi-modal intervention (NSAIDs, manual 
therapy, exercise and stretching). 
Outcome measures that reported on symptoms, physical 
function (e.g. return to sport), quality of life (QOL) and rat-
ings of success were included. Short (≤ 12 weeks), medi-
um (> 12 weeks - 1 year) and long (≥ 1 year) time-points 
were considered. Adverse events were reported as a sec-
ondary outcome, and were dichotomised as minor or ma-
jor.10 Minor adverse events were defined as incidents which 
had minimal serious or potentially serious effects, such as 
thigh paraesthesia or a small infection that resolved with 
anti-microbial drugs. Major adverse events were incidents 
that had the potential for severe effects, such as deep vein 
thrombosis or severe infection. 
One amendment was made from the initial protocol. 
Originally only case series were included. This was amend-
ed to exclude case series with <10 participants. This was 
identified as an oversight in the initial protocol and was re-
vised prior to conducting the search. This amendment re-
sulted in the exclusion of three case series with small sam-
ple sizes.11–13 
Pre-specified data was extracted from each study and in-
cluded eligibility criteria, study design, participant demo-
graphics, intervention, outcome parameters, results at all 
time points and adverse events. Data was extracted by one 
reviewer (AN) and checked by a second reviewer (AS). Au-
thors were contacted in the case of missing data. If au-
thor(s) did not respond, they were contacted again after two 
weeks. If the author(s) still did not respond raw data was re-
ported. 
Means and standard deviations of continuous outcomes 
for comparative studies (e.g. intervention A vs Intervention 
B) were converted to standardized mean differences (SMD)
with 95%CI using RevMan (version 5.3). When studies re-
ported changes over time, means and standard deviations
(SD) were converted to standardized paired differences
(SPD) using the ‘metafor’ package (version 2.1-0) within the
‘R’ statistical software package (version 3.5.1). SPD calcu-
lations (with 95% CI) require information about pre- and
post-test reliability.14,15 If this was not reported, or could
not be located, a conservative estimate was used (r=0.50).
In cases where the SD was not reported, we used the for-
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Figure 1: PRISMA flow chart illustrating study selection process 
mula provided in the Cochrane Handbook (section 16.1.3.2), 
using a conservative correlation coefficient of 0.5, to calcu-
late the SD.16 Effect sizes (SMDs and SPDs) of 0.2, 0.5 and 
0.8 were considered as small, medium and large respective-
ly.17 When data could not be presented as a SPD, raw da-
ta were presented. The proportion of people who returned 
to pre-injury level of sport was summarized as a percent 
with 95% confidence interval (CI). Statistical heterogeneity 
across pooled studies was assessed using the Tau ( ) and 
I2 statistic. An I2 value of 25%, 50% or 75% was considered 
a low, moderate or high level of heterogeneity respective-
ly.18 The ‘meta’ package, version 4.9-2, of the R statistical 
software package (version 3.3.1) was used for all statistical 
analyses (http://www.r-project.org/). 
Study quality was assessed using two separate risk of bias 
tools, depending on study design.16 The Cochrane Risk of 
Bias Tool was used to assess RCTs.16 Each of the eight do-
mains were marked as either low risk of bias (+), high risk of 
bias (-) or unclear risk of bias (?).16 Studies with the pres-
ence of three or more (-) or (?) were considered as having 
a high risk of bias. The Joanna Briggs Institute Checklist 
was used to assess the risk of bias in other study designs.19 
Items were scored “yes (Y)”, “no (N)”, “unclear (U)” or “not 
applicable (N/A)” on the ten point checklist.19 If an individ-
ual study scored ≥ 6 “yes (Y)” scores, it was considered low 
risk of bias. 
Completeness of reporting in intervention and control 
groups was assessed using relevant items of the Template 
for Intervention Description and Replication Checklist (TI-
DieR).20 Improved reporting provides an opportunity to un-
derstand the treatments used and more precisely inform 
clinicians about the type of interventions, enabling replica-
tion of treatments in clinical practice. If items were not rel-
evant for an included study, they were scored not applicable 
(N/A). For example, completeness of reporting of a control 
group was scored N/A in studies where there was no con-
trol/comparison. 
Both single group and comparative studies were assessed 
according to the GRADE guidelines.21 Overall quality was 
defined as high, moderate, low or very low.21 A staged 
process was followed whereby RCTs were first rated as high 
and case series were rated as low-quality evidence.22 Fol-
lowing this step, quality of evidence for individual out-
comes were further reviewed, with the potential of being 
further downgraded by one level for each of the following 
factors: i) limitations in design (≥25% of the participants 
from studies with a high risk of bias as determined by the 
risk of bias tool), ii) inconsistency of results (significant 
statistical heterogeneity (I2 >40%) or inconsistent findings 
across studies (≤75% of the participants report findings in 
the same direction), iii) indirectness (i.e. generalization of 
the findings), iv) imprecision (total number of participants 
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<300 for each outcome and wide confidence intervals) and 
v) other considerations (e.g. publication bias, flawed design,
massive dropout).23,24 Single studies (n<300) were consid-
ered inconsistent and imprecise, providing “low quality ev-
idence”, which could be further downgraded to very low-
quality evidence if additional items were not satisfied.23,24 
RESULTS
The PRISMA flow diagram, is shown in Figure 1. 1924 stud-
ies were identified through database searching. Full texts of 
34 studies were assessed for inclusion. Twelve studies met 
inclusion criteria. 
Participant characteristics, study design and diagnostic 
criteria are displayed in Table 1. A total of 424 (229 males, 
195 females) participants were included. Mean ages in in-
dividual studies ranged from 24 to 51 years. One-hundred 
and ninety-nine (47%) participants were described as pro-
fessional, competitive or high-level athletes, 75 (18%) were 
recreational athletes and five participants were non-ath-
letes. Activity levels in 145 (34%) participants were not re-
ported. 
The majority of studies used clinical assessment and 
imaging to diagnose proximal hamstring tendinopathy 
(Table 1). The clinical assessments varied between studies. 
Imaging (magnetic resonance imaging or ultrasound) was 
used to attempt to verify proximal hamstring pathology in 
92% of studies. A variety of patient reported physical func-
tion measures and pain measures were used. Mean follow-
up times varied from one week to six years. 
The most common intervention was platelet-rich plasma 
injection.25–29 Other interventions included surgery,2,4,5,8 
corticosteroid injection,30,31 autologous whole blood injec-
tion,25 shockwave therapy1 and multi-modal intervention 
(NSAIDs, manual therapy, exercise and stretching).27,32 
Name and description (item 1) and mode of delivery 
[item 6 (a) and (b)] were reported completely in both in-
tervention and control groups (Figure 5). Intervention ad-
herence (TIDieR items 11 and 12) was not reported in any 
study. No studies provided adequate details of post-surgical 
rehabilitation protocols. Risk of bias for RCTs and case se-
ries are reported in Figure 2 and Figure 3 respectively. 
EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS
There was very low-level evidence from a single RCT that 
shockwave therapy was more effective than a multi-modal 
intervention (one week of rest plus NSAIDs, two weeks of 
manual therapy and therapeutic ultrasound, and three 
weeks of exercise - including strength training and stretch-
ing) by a large effect in the short (-1.84 SMD; 95% CI -2.59, 
-1.09), medium (-3.23 SMD; 95% CI -4.28, -2.19) and long-
term (-3.22 SMD; 95% CI -4.28, -2.16) on self-reported
symptoms (Table 2).1 There was also very low-level evi-
dence that shockwave therapy was more effective than the
multi-modal intervention by a large effect in the short-term
(-3.09 SMD; 95% CI -4.04, -2.15), medium (-2.90 SMD; 95%
CI -3.88, -1.92) and long-term (-2.42 SMD; 95% CI-3.33,
-1.50) on physical function.1 Sixteen athletes (80%) re-
Figure 2: Risk of bias in RCTs 
Figure 3: Risk of bias in case series 
turned to pre-injury level of sport, at a mean time of nine 
weeks (range; 6-15 weeks) post shockwave therapy inter-
vention (Figure 4). No participants in the multi-modal in-
tervention group returned to sport at one year.1 
There was very-low level evidence from a single RCT of 
no significant difference between platelet-rich plasma and 
autologous whole blood injection on physical function in 
the short [(0.03 SMD; 95% CI -0.96, 1.03) to (0.28 SMD 95% 
CI -0.76, 1.32)] and medium-term [(0.17 SMD; 95% CI -0.86, 
1.21) to (0.24 SMD; 95% CI -0.76, 1.24)]. There was also very 
low-level evidence of no difference between interventions 
on quality of life in the short (0.01 SMD; 95% CI-1.00, 1.03) 
and medium-term (-0.04 SMD; 95%CI -1.05, 0.97).25 One 
complication occurred after platelet-rich plasma injection 
(irritation of the sciatic nerve).25 
Proximal Hamstring Tendinopathy: A Systematic Review of Interventions
International Journal of Sports Physical Therapy
Table 1: Patient Characteristics 
Study 
(Year) 
n (F), mean age (years) Diagnostic criteria Tendon involved 
(%) 





40 (13F), SWT 24 years, multi-modal intervention 
24 years 
At least 2 of the following painful; Puranen Orava test, fast 












15 (13F), AWB: 45.4 years, PRP 47 years, 17 cases 
(2 bilateral) 
Clinical diagnosisa 
Positive MRI or US 




17 (5F), 27 years Reporting pain at ischial tuberosity 
Pain with concentric hamstring contraction: (positive 47%) 
Tenderness ischial tuberosity (41% positive) 
Puranen Orava test (88% positive) 














23 months (3-48) 
Fader 
(2014) 
18 (12F), 43 years Clinical diagnosisa 
MRI 
NR NR 32.6 months (6-120) 
Krauss 
(2016) 
14 (13F), 47 years At least 2 of the following; 
Tenderness to palpation at ischial tuberosity, positive bent 
knee stretch test, positive supine plank test 
MRI 
NR NR 4.1 years (5 months 
to 10 years) 
Lempainen 
(2009) 
90 (32F), 34 years, 
103 casesb (13 bilateral) 
Patient interview and history 










29 (22F), 45 years Clinical diagnosisa confirmed with positive MRI NR NR NR 
Nicholson 
(2014) 
18 (10F), 51 years, 22 cases (4 bilateral) Pain with prolonged sitting 
Pain with hamstring contraction 
MRI 
NR Athletes: 18 28 months (2-120) 
Puranen 
(1988) 
59 (14F), Athletes: 25 years, joggers: 39 years, non-
athletes: 35 years, 65 cases (6 bilateral) 
Pain on active stretching 
Pain on palpation 






15 (8F), 38 years, 17 cases (2 bilateral) Clinical diagnosisa 
MRI 
NR PRP group: 
Collegiate or high-










PRP: 9.6 months 
Young 
(2008) 
44 (16F), 29 years, 47 cases (3 bilateral) Pain on palpation of proximal hamstring region 
Weakness at 30º of resisted knee flexion 
MRI/US 




8 cases: < 6 months 
15 cases: 6-12 
months 




n (F), mean age (years) Diagnostic criteria Tendon involved 
(%) 
Activity level Average duration of 
symptoms (range) 




65 (37F), 37.7 years Clinical diagnosisa 
MRI/US 
NR NR 8 cases: < 6months 
15 cases: 6 months 
to 1 year 
15 cases: > 1 year 
AWB = autologous whole blood injection, F = female, MRI = magnetic resonance imaging, NR = not reported, PRP = platelet-rich plasma injection, SWT = shockwave therapy, US = ultrasound 
Figure 4: Return to pre-injury level of sport 
Figure 5: Reporting of intervention and control group 
EVIDENCE FROM CASE SERIES
Three studies, recording the results of platelet-rich-plasma 
injection alone, documented change in self-reported symp-
toms over time (Table 2).26,27,29 Outcomes could not be 
pooled due to heterogeneity in measures and incomplete 
data reporting. There was very low-level evidence that PRP 
is associated with a large reduction in symptoms over the 
short-term (-0.92 SPD; 95% CI -1.54, -0.29).29 A second 
study found very low-level evidence that platelet-rich plas-
ma injection was associated with a small, clinically sig-
nificant, reduction in self-reported symptoms (Table 2).26 
Two studies reported changes in physical function follow-
ing platelet-rich plasma injection(s) over time (Table 
2).28,29 There was very low-level evidence of a small (-0.44 
SPD; 95% CI -0.82, -0.06)28 to large (-0.90 SPD; 95% CI 
-1.52, -0.28)29 improvement in physical function in the
short-term (Table 2). Ten per cent of participants returned
to their pre-injury level of sport after platelet-rich plasma
injection at eight weeks (Figure 4).28 Two (4%) minor ad-
verse events occurred (short-term high levels of pain post-
injection).26,28 
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Table 2: Results 
Study 
(Year) 
Intervention Mean follow up (range) Symptoms 
Effect size (CI) unless 
otherwise stated 
(-ve indicates reduction in 
pain) 
Physical function 
Mean effect size (CI) unless 
otherwise stated 
Adverse effects 





Multi-modal intervention: NSAIDs, manual therapy, 
exercise and ultrasound 
SWT: 2500 impulses at 0.18 mJmm2/ frequency = 10 
shocks in 4 separate sessions at weekly intervals. 
1 week, 6 months, 12 months Patient reported pain 
rating: 
VAS: 
-ve favours SWT 
Patient reported physical 
function: 
NPRS: 
-ve favours SWT 







PRP vs AWB 
Single U/S guided injection of AWB (5mL) or PRP (3mL). 
12 weeks, 6 months NR Patient reported physical 
function: 
HOS (ADL): 
-ve favours PRP 
HOS (SPORT): 
-ve favours PRP 
MHHS: 
-ve favours PRP 




• Week 1: -1.84 (-2.59, -1.09) 
SMDa 
• 6 months: -3.23 (-4.28, 
-2.19) SMDa 
• 12 months: -3.22 (-4.28, 
-2.16) SMD 
• 1 week: -3.09 (-4.04, -2.15) SMD 
• 6 months: -2.90 (-3.88, -1.92) 
SMD 
• 12 months: -2.42 (-3.33, -1.50) 
SMD 
• SWT: 16/20 (80%) mean time of 9 
weeks (range, 6-15 weeks). 
• Multi-modal intervention: 0/20 
(0%) 
• SWT: 0 (0%) 
• Multi-modal interven-
tion: 0 (0%) 
• SWT: 0 (0%) 
• Multi-modal interven-
tion: 0 (0%) 
• 6 weeks: -0.56 (-1.58, 0.45) SMD 
• 12 weeks: 0.03 (-0.96, 1.03) SMD 
• 6 months: NR 
• 6 weeks: -0.21 (-1.24, 0.83) SMD 
• 12 weeks: 0.28 (-0.76, 1.32) SMD 
• 6 months: 0.17 (-0.86, 1.21) SMD 
• 6 weeks: -0.28 (-1.28, 0.72) SMD 
• 12 weeks: 0.05 (-0.95, 1.04) SMD 
• 6 months: 0.24 (-0.76, 1.24) SMD 
• 6 weeks: -0.80 (-1.86, 0.26) SMD 
• 12 weeks: 0.01 (-1.00, 1.03) SMD 
• 6 months: -0.04 (-1.05, 0.97) 
• PRP: 1 (10%) 
• AWB: 0 (0%) 
• PRP: 0 (0%) 
• AWB: 0 (0%) 
Study 
(Year) 
Intervention Mean follow up (range) Symptoms 
Effect size (CI) unless 
otherwise stated 
(-ve indicates reduction in 
pain) 
Physical function 
Mean effect size (CI) unless 
otherwise stated 
Adverse effects 
(number %): minor, 
major 





Prone incision from ischial tuberosity to 8-15cm distally. 
Partial transverse tenotomy performed plus sciatic nerve 
release. 
71.3 months (24-138) Patient reported pain 
rating: 
VAS: 
Patient reported physical 
function: 
Tegner score: 







A single U/S guided injection (2.5-4mL). 
46 months Patient reported pain 
rating: 
VAS (mean pain): 







Single U/S guided injection (4mL) + needle tenotomy (5 
passes). 
12 weeks Patient reported pain 
rating: 
VAS (mean pain): 




4 (29%) had worse 
physical function at 




Prone, transverse or longitudinal incision. Transverse 
tenotomy performed on semimembranosus + adhesions 
freed around sciatic nerve as required. 
49 months (range, 12-156 
months) 







Single U/S guided injection (6mL) 
8 weeks NR Patient reported physical 
function: 





• -6.02 (-8.10, -3.94) SPDa • -4.08 (-5.53, -2.63) SPDc 
• Proportion: 17/17 (100%) re-
turned to pre-injury level at aver-
age of 4.4 (range 2-9 months) 
• 1 (6%) 
• 1 (6%) 
• -2.9 MDa 
• 10 (55.6%) patients had an 
80% or greater improve-
ment at 6 months 
• 1 (6%) 
• 0 (0%) 
• -0.92 (-1.54, -0.29) SPDa • -0.90 (-1.52, -0.28) SPDc 
• Proportion: 80/90 (89%) mean 5 
months 
• 3 (3%) 
• 1 (1%) 
• VISA H: -0.44 SPD (-0.82, -0.06) 
• 1 (3%) 
• 0 (0%) 
Study 
(Year) 
Intervention Mean follow up (range) Symptoms 
Effect size (CI) unless 
otherwise stated 
(-ve indicates reduction in 
pain) 
Physical function 
Mean effect size (CI) unless 
otherwise stated 
Adverse effects 





Single injection under fluoroscopic guidance 
21 months (VAS) 
24.8 months (LEFS) 
Patient reported pain 
rating: 
VAS: 
Improvement in symptoms 
short term (proportion): 
Improvement in symptoms 
> 3 months (proportion): 
Patient reported physical 
function: 
LEFS/80: 







65% modified Kocher incision with patient lying on 
unaffected side. 35% straight incision over lower edge of 
gluteus maximus with patient prone. Taut structures of 
hamstring at ischial tuberosity divided and tendon ends 
separated, freeing sciatic nerve. 




Multi-modal intervention (physical therapy + NSAIDs) vs 
failed multi-modal intervention + single volume PRP 
injection (6cc) plus additional multi-modal intervention 
Mulit-modal intervention: 2 
months 
Failed multi-modal intervention 
(PRP + multi-modal 
intervention): 4.5 months 
Patient reported pain 
rating: 
VAS: 
Patient reported physical 
function: 
NPRS: 








Semi-prone, incision in gluteal fold to gluteus maximus 
dissection continued toward ischial tuberosity. Sciatic 
53 months (range, 9-110) Patient reported pain 
rating: 
VAS: 
Patient reported physical 
function: 
Weakness score (/10): 
Minor: 
• Proportion: 3/29 (10%) at 8 
weeks 
• -3.28 MDa 
• Yes: 14 (78%) 
• No: 4 (22%) 
• Yes: 8 (44%) 
• No: 10 (56%) 
• 60 (48, 72) e 
• Increased from 28.76% to 
68.82% 
• 0 (0%) 
• 0 (0%) 
• Proportion: 52/59 (88%) f • 4 (6%) 
• 0 (0%) 
• Multi-modal intervention: 
-6.2 MDa 
• Failed multi-modal inter-
vention (PRP + multi-modal 
intervention): -7.5 MDa 
• Multi-modal intervention: -2.2 
MDc 
• Failed multi-modal intervention 
(PRP + multi-modal interven-
tion): -4 MDc 
• Multi-modal intervention: 2/11 
(18%) 
• Failed multi-modal intervention 
PRP + multi-modal intervention: 
9/9 (100%) 
• 0 (0%) 
• 0 (0%) 
Study 
(Year) 
Intervention Mean follow up (range) Symptoms 
Effect size (CI) unless 
otherwise stated 
(-ve indicates reduction in 
pain) 
Physical function 
Mean effect size (CI) unless 
otherwise stated 
Adverse effects 
(number %): minor, 
major 
nerve freed and prominent bursal tissue removed. 
-ve indicates reduction in 





Single CSI to area of maximum pain under U/S guidance. 48 months (6-96) Patient reported rating: 




AWB: autologous whole blood, CI: confidence interval, HOS: Hip Outcome Score, i-HOT: International Hip Outcome Tool, LEFS: Lower Extremity Functional Scale, MHHS: Modified Hip Harris Score, NR: not reported, NRPS: Nirschl Phase Rating Scale , PRP: platelet-rich plasma, RCT: ran-
domised controlled trial, RTS: return to sport, SPD: standard paired difference, SMD: standard mean difference, SWT: shockwave therapy, U/S: ultrasound, VAS: Visual Analogue Scale, VISA H: Victorian Institute of Sport Assessment-proximal hamstring tendon 
a Negative indicates an improvement in pain 
b Positive indicates improvement in weakness score 
c Negative indicates an improvement in physical function 
d Adverse effects not reported on separately from complete tendon ruptures within study 
e Measure taken post-operatively only 
f Level of return to sport not reported 
• -1.89 (-2.36, -1.41) SPDa • -3.69 (-2.76, -4.62) MDc 
• Proportion: 34/44 (77%) 
• 11 (23%) 
• 0 (0%) 
• Complete: 11 (29%), mod-
erate: 8 (21%), mild: 10 
(26%), no: 9 (24%) 
• 0 (0%) 
• 0 (0%) 
A single retrospective case series investigated the change 
in outcomes before and after PRP, in those who had failed a 
multi-modal intervention (physical therapy + non-steroidal 
anti-inflammatory drugs).27 Failure was determined by per-
sistence of symptoms and an inability to return to baseline 
activity after the multi-modal intervention had been com-
pleted.27 There was very low-level evidence of an improve-
ment in symptoms and physical function over time (Table 
2).27 In this study, all athletes who were unable to return 
to sport with multi-modal intervention alone, returned to 
sport post PRP plus multi-modal intervention (Figure 4).27 
Two studies reported change in self-reported symptoms 
after surgery (Table 2).2,8 There was very low-quality evi-
dence of a large reduction in symptoms in the long-term 
[(-1.89 SPD; 95% CI -2.36, -1.41) to (-6.02 SPD; 95% CI 
-8.10, -3.94)].2,8 There was very low-quality evidence from
a single study of a large improvement in physical function
in the long-term (4.08 SPD; 95%CI -5.53, -2.63) .2 Return
to pre-injury level of sport following surgery ranged from
77-100%,2,4,5,8 with two studies reporting on mean return
to sport time to pre-injury level (4.4 to 5 months).2,5 One
study reported that 88% of participants returned to sport,
but did not report whether participants returned to their
pre-injury level.4 
Adverse events were reported in all studies investigating 
outcomes of surgery (Table 2).2,4,5,8 One study did not pro-
vide sufficient detail to allow events to be dichotomized as 
minor or major.4 Complications occurred in 21 (10%) cases 
(Table 2). Type and severity of complications varied. Nine-
teen (9%) patients experienced minor complications. Ex-
amples included: notable post-operative soreness5 and in-
termittent thigh paraesthesia that resolved spontaneously.2 
Two (1%) patients experienced major complications, which 
included wound abscess requiring surgical drainage2 and 
deep vein thrombosis.5 
Management of proximal hamstring tendinopathy with 
corticosteroid injection was described in two studies.30,31 
Both described change in self-reported symptoms over time 
(Table 1).30,31 One study provided very low-level evidence 
of clinically significant improvement in self-reported symp-
toms the long-term (Table 2).30 Both studies reported on 
long-term symptom resolution.30,31 One study found that 
56% of patients did not experience improvement greater 
than three months.30 The other study found that 56% still 
reported symptoms at long-term follow up.31 A single study 
reported on physical function (post-intervention only), as 
a percentage of full activity, and found activity level in-
creased by 40% in the long-term (mean 24.8 months).30 No 
adverse events were reported.30,31 
DISCUSSION
The primary aim was to evaluate surgical and non-surgical 
interventions used to manage proximal hamstring 
tendinopathy. Three main findings emerged from the sys-
tematic review: i) there is a lack of rigorous RCTs comparing 
treatment interventions, ii) patient selection criteria and 
use of outcome measures are inconsistent across studies, 
and iii) there is inadequate description of treatment inter-
ventions used. 
Of the twelve studies that met inclusion criteria, only 
two were RCTs. Both were confounded by small sample 
sizes. There was no high or moderate quality evidence for 
any intervention (symptoms, physical function or QOL). 
There was very low-level evidence from a single study to 
suggest that shockwave therapy was more effective than 
a multi-modal intervention (exercise, manual therapy, 
NSAIDs, ultrasound) in professional athletes, at both medi-
um and long-term time points.1 While there were limita-
tions in completeness of reporting on adverse events, 
surgery resulted in the highest level of minor and major ad-
verse events. 
Injection therapies may be an attractive option because 
they are less invasive than surgery.33 While multiple types 
of injections were reported (platelet-rich plasma, corticos-
teroid and autologous whole blood), the overall quality of 
evidence for all injections in proximal hamstring 
tendinopathy was found to be low or very low (Table 3). 
Consequently, at this stage it is not possible to recommend 
any type of injection over another or no injection. 
Corticosteroid injections are a commonly prescribed 
treatment for tendinopathy. While it is important to con-
sider the limitation in overall quality of evidence for cor-
ticosteroid injection in this review, the findings in a single 
group case series indicate a positive change in symptoms 
over time in the short-term (Table 2). Systematic reviews of 
high quality RCTs in tendinopathies, which compared cor-
ticosteroid injection to other interventions, found a similar 
trend of a positive short-term effect on symptoms, that are 
nullified in the medium and long-term.34,35 While this early 
improvement is desirable, it is worth noting that corticos-
teroid injection has been associated with delayed healing 
compared to wait and see (lateral epicondylagia)36,37 and 
increased collagen disorganization and necrosis in vitro.38 
The popularity and cost of regenerative therapies war-
rants continued research to improve the evidence base.39 
This systematic review found no high or moderate quality 
evidence for platelet-rich plasma injection; therefore, its 
utility remains uncertain in this condition. Its effect on 
symptoms in other tendinopathies was recently summa-
rized in a systematic review.40 The authors reported that 
platelet-rich plasma injections were more efficacious than 
alternative injections on pain severity in tendinopathies 
(0.47, CI 95% 0.22 to 0.72).40 However, it is worth noting 
that there were several limitations, including the type of in-
jections used as comparisons (e.g. corticosteroid injection 
or saline) and the tendon involved. 
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Table 3: Summary of findings (RCTs and case series) 
No. of patients/studies Limitations in Design Inconsistency Indirectness Imprecision Publication bias Effect estimate Certainty 
RCTs 
SWT vs multi-modal intervention: VAS (follow up: 1 week; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: VAS (follow up: 6 months; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: VAS (follow up: 12 months; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: subjective rating of improvement (follow up: 1 week; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: subjective rating of improvement (follow up: 6 months; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: subjective rating of improvement (follow up: 12 months; self-reported symptoms) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: NRPS (follow up: 1 week; physical function) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: NRPS (follow up: 6 months; physical function) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: NRPS (follow up: 12 months; physical function) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: return to pre-injury level of sport (follow up: 12 months; physical function) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
SWT vs multi-modal intervention: adverse events (follow up: 12 months) 
40/1 Serious a Serious b Not serious Serious d Not serious e Large (favours SWT) ●○○○ VERY LOW 
PRP vs AWB: HOS ADL (follow up: mean 6 weeks; physical function) 
17/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: HOS ADL (follow up: 12 weeks; physical function) 
17/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: HOS Sport (follow up: 6 weeks; physical function) 
15/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: HOS Sport (follow up: 12 weeks; physical function) 
15/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: HOS Sport (follow up: 6 months; physical function) 
15/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: iHOT 33 (follow up: 12 weeks; physical function) 
16/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: iHOT 33 (follow up: 6 months; physical function) 
16/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: MHHS (follow up: 12 weeks; physical function) 
17/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: MHHS (follow up: 6 months; physical function) 
No. of patients/studies Limitations in Design Inconsistency Indirectness Imprecision Publication bias Effect estimate Certainty 
17/1 Serious a Serious b Not serious Serious d Not serious e No apparent difference between groups ●○○○ VERY LOW 
PRP vs AWB: adverse effects (follow up: 6 months) 
17/1 Serious a Serious b Not serious Serious d Not serious e Not estimable ●○○○ VERY LOW 
Case series 
Surgery: VAS (follow up: 53-71 months; self-reported symptoms) 
61/2 Serious a Serious c Seriousf Serious d Not serious e Large ●○○○ VERY LOW 
Surgery: Tegner Score (follow up: mean 71 months; physical function) 
17/1 Serious a Serious b Seriousf Serious d Not serious e Large ●○○○ VERY LOW 
Surgery: subjective weakness score (follow up: mean 53 months; physical function) 
44/1 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
Surgery: return to pre-injury level of sport (follow up: 49-71 months; physical function) 
151/3 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
Surgery: return to undefined level of sport (follow up: mean 24 months; physical function) 
59/1 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
Surgery: adverse effects (follow up: 24-71 months) 
179/4 Serious a Not serious Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
Multi-modal intervention: vs multi-modal intervention: + delayed PRP + multi-modal intervention: NRPS (follow up: 4 and 4.5 months; physical function) 
17/1 Serious a Serious Seriousf Serious Not serious Not estimable ●○○○ VERY LOW 
PRP: VISA H (follow up: 8 weeks; physical function) 
29/1 Serious a Serious b Seriousf Serious d Not serious e Small ●○○○ VERY LOW 
PRP: LEFS (follow up: 12 weeks; physical function) 
14/1 Serious a Serious b Seriousf Serious d Not serious e Large ●○○○ VERY LOW 
PRP: adverse effects (follow up: 8 weeks-46 months) 
47/2 Serious a Not serious Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
PRP: adverse effects (follow up: 12 weeks) 
14/1 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
CSI: VAS (assessed with: mean 21 months self-reported symptoms) 
18/1 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
CSI: LEFS (follow up: mean 21 months; physical function) 
18/1 Serious a Serious b Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
CSI: adverse effects (follow up: 21-48 months) 
83/2 Serious a Not serious Seriousf Serious d Not serious e Not estimable ●○○○ VERY LOW 
AWB: autologous whole blood injection, CI: confidence interval, CSI: corticosteroid injection, HOS: Hip Outcome Score, HOS-sport: Hip Outcome Score: sport, HOS-ADL: Hip Outcome Score: activities of daily living, iHOT-33: International Hip Outcome Tool, LEFS: Lower Extremity Functional Scale, 
MHHS: Modified Hip Harris Score, NA: not applicable, NRPS: Nirschl Phase Rating Scale, PRP: platelet-rich plasma injection, RCT: randomised controlled trial, SMD: standardised mean difference, SWT: shockwave therapy, VAS: Visual Analogue Scale, VISA H: Victorian Institute of Sport Assessment-
proximal hamstring tendon 
a ≥ 25% of the participants from studies with a high risk of bias 
b Single study (n<300) 
c I2 > 40% 
d Pooled data with < 300 participants for an outcome 
e The possibility of publication bias is not excluded, but was not considered sufficient to downgrade the quality of evidence 
f No head-to-head comparison 
Shockwave therapy has been proposed for a host of upper 
and lower limb tendinopathies,1,41–43,43,44,44,45 and other 
musculoskeletal conditions.46,47 This systematic review 
found preliminary support that shockwave therapy was su-
perior to a multi-modal intervention (exercise, manual 
therapy, NSAIDs, ultrasound) for improving symptoms and 
physical function. However, as there was only a single study 
on shockwave therapy in proximal hamstring tendinopathy, 
with a small sample size, the results may not be representa-
tive of the wider population.1 Furthermore, there are sever-
al factors that may have made the comparison group (mul-
ti-modal intervention) less effective. In this study, exercise 
was included for three-weeks of the six-week program. In 
the literature, successful rehabilitation programs for other 
lower limb tendinopathies consistently report significant-
ly longer time-frames.48–50 Avoiding excessive compressive 
load on the tendon at the enthesis has also been proposed 
to be a consideration in early to mid-stage exercise selec-
tion.6,51 In the multi-modal intervention (exercise, manual 
therapy, NSAIDs, ultrasound), exercises selected likely 
placed the insertion of the proximal hamstring tendon un-
der high levels of compression, early in rehabilitation 
(lunge, hamstring stretch, exercise bike).1 For further infor-
mation regarding a management program consistent with 
these parameters, readers are directed to a narrative re-
view.6 
In managing tendinopathy, surgical interventions are 
typically reserved for recalcitrant cases that have not yet re-
solved with other interventions. While there were improve-
ments over time following surgery (symptoms and physical 
function) in case series studies without comparator groups, 
it is unknown if these are real treatment effects or whether 
results are caused by other factors, such as natural history 
or postoperative rehabilitation. An insight into the likely 
treatment effects of surgery may be gleaned from a recent 
systematic review of upper and lower limb tendinopathy, 
which found surgery was not superior to sham surgery or 
physiotherapy on pain, function, range of motion and suc-
cess ratings in the longer term.52 Recommendations were 
that surgery should not be seriously entertained until 12 
months of an evidence based loading program has been 
credibly trialled.52 Until such time as there are adequately 
designed comparator studies, these recommendations 
should also be applied to proximal hamstring tendinopathy. 
A limitation of this review was the lack of high-quality 
trials with consistent patient outcome measures, inclusion 
criteria and time points. The findings highlight the need for 
consensus on patient selection criteria, outcome measures 
and frequency of follow up, to allow the pooling of data. An-
other limitation was the high number of pre-post study de-
signs. SPDs were calculated in an attempt to provide a stan-
dardized measure across study designs. It is important that 
these SPDs are not misconstrued as treatment effects, be-
cause there were no randomized comparisons that remove 
confounders such as regression to the mean, natural recov-
ery and testing. Consequently, these studies were discussed 
separately from comparative designs.53 Interventions such 
as load management, heavy slow, strength training, 
platelet-rich plasma vs placebo and shockwave vs sham 
shockwave should be avenues for future research. Future re-
search should prospectively report post-surgical protocols 
and adherence to interventions. 
CONCLUSION
There was very low-level evidence that shockwave therapy 
was more effective than a multi-modal intervention. There 
was very low-level evidence of no difference between autol-
ogous whole blood injection and platelet-rich plasma injec-
tion. Results of this systematic review highlight the need 
for high-quality studies and the standardization of selec-
tion criteria, outcomes and reporting across studies. This 
will assist in determining the most effective option for man-
agement of proximal hamstring tendinopathy. 
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APPENDIX 
Table 4: Medline Search 
Date 30.01.2019 
Set Results 
# 3 658 #2 AND #1 
Indexes=MEDLINE Timespan=All years 
# 2 56,973 (((TOPIC: (tendinopathy) OR TOPIC: (tendinitis)) OR TOPIC: (tendinosis)) OR TOPIC: (tear)) 
Indexes=MEDLINE Timespan=All years 
# 1 13,288 (((TOPIC: (hamstring) OR TOPIC: (biceps 
femoris)) OR TOPIC: (semitendinos*)) OR TOPIC: (semimembranos*)) 
Indexes=MEDLINE Timespan=All years 
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